The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1323
ISSUE1323
October 19, 2009
Recombinant Human Antithrombin (ATryn)
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Recombinant Human Antithrombin (ATryn)
October 19, 2009 (Issue: 1323)
The FDA has approved the use of recombinant human antithrombin (rhAT; ATryn - Lundbeck) in patients with inherited antithrombin (AT) deficiency to prevent thrombosis during or after surgery or childbirth. The protein is produced in the milk of...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.